{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:30:15Z","timestamp":1792639815385,"version":"4.5.0"},"reference-count":135,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T00:00:00Z","timestamp":1513036800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Owing to the rarity of peripheral T-cell lymphoma (PTCL) and the heterogeneity of subtypes, there are no compelling data to guide the therapeutic approaches for such patients. Over the years, there have been remarkable advances in molecular subtyping and treatment of PTCL, although there are still many areas to be explored. In this review, we summarize recent updates on the evolution of understanding and treatment for PTCL.<\/ns4:p>","DOI":"10.12688\/f1000research.12573.1","type":"journal-article","created":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T11:50:14Z","timestamp":1513079414000},"page":"2123","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Recent advances in understanding and managing T-cell lymphoma"],"prefix":"10.12688","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1499-7131","authenticated-orcid":false,"given":"Jun Ho","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2017,12,12]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"2375-2390","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms.","volume":"127","author":"S Swerdlow","year":"2016","journal-title":"Blood."},{"key":"ref-2","first-page":"3909-18","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.","volume":"89","year":"1997","journal-title":"Blood."},{"key":"ref-3","doi-asserted-by":"crossref","first-page":"45-50","DOI":"10.1093\/oxfordjournals.annonc.a057673","article-title":"Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives).","volume":"1","author":"B Coiffier","year":"1990","journal-title":"Ann Oncol."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"627-33","DOI":"10.1182\/blood.V99.2.627","article-title":"Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10.","volume":"99","author":"A Attygalle","year":"2002","journal-title":"Blood."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"4952-63","DOI":"10.1182\/blood-2006-10-055145","article-title":"The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells.","volume":"109","author":"L de Leval","year":"2007","journal-title":"Blood."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"432-9","DOI":"10.3324\/haematol.2009.010991","article-title":"The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation.","volume":"95","author":"T Marafioti","year":"2010","journal-title":"Haematologica."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"1466-9","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters.","volume":"120","author":"F Lemonnier","year":"2012","journal-title":"Blood."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"371-5","DOI":"10.1038\/ng.2916","article-title":"A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma.","volume":"46","author":"H Yoo","year":"2014","journal-title":"Nat Genet."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"166-70","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas.","volume":"46","author":"T Palomero","year":"2014","journal-title":"Nat Genet."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"171-5","DOI":"10.1038\/ng.2872","article-title":"Somatic RHOA mutation in angioimmunoblastic T cell lymphoma.","volume":"46","author":"M Sakata-Yanagimoto","year":"2014","journal-title":"Nat Genet."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"1901-3","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.","volume":"119","author":"R Cairns","year":"2012","journal-title":"Blood."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"2915-23","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma.","volume":"123","author":"J Iqbal","year":"2014","journal-title":"Blood."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"5496-504","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.","volume":"111","author":"K Savage","year":"2008","journal-title":"Blood."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"1473-80","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.","volume":"124","author":"E Parrilla Castellar","year":"2014","journal-title":"Blood."},{"key":"ref-15","doi-asserted-by":"crossref","first-page":"554-5","DOI":"10.1097\/00006534-199708000-00065","article-title":"Anaplastic T-cell lymphoma in proximity to a saline-filled breast implant.","volume":"100","author":"J Keech","year":"1997","journal-title":"Plast Reconstr Surg."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"114-20","DOI":"10.1200\/JCO.2013.52.7911","article-title":"Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients.","volume":"32","author":"R Miranda","year":"2014","journal-title":"J Clin Oncol."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"306-14","DOI":"10.1093\/annonc\/mdv575","article-title":"Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes.","volume":"27","author":"C Laurent","year":"2016","journal-title":"Ann Oncol."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"555-7","DOI":"10.1038\/leu.2010.295","article-title":"Nuclear expression of MATK is a novel marker of type II enteropathy-associated T-cell lymphoma.","volume":"25","author":"S Tan","year":"2011","journal-title":"Leukemia."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"1688-96","DOI":"10.1038\/leu.2013.41","article-title":"Type II EATL (epitheliotropic intestinal T-cell lymphoma): a neoplasm of intra-epithelial T-cells with predominant CD8\u03b1\u03b1 phenotype.","volume":"27","author":"S Tan","year":"2013","journal-title":"Leukemia."},{"key":"ref-20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12602","article-title":"Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations.","volume":"7","author":"A Roberti","year":"2016","journal-title":"Nat Commun."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"3599-606","DOI":"10.1182\/blood-2013-07-512830","article-title":"Indolent T-cell lymphoproliferative disease of the gastrointestinal tract.","volume":"122","author":"A Perry","year":"2013","journal-title":"Blood."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"e68343","DOI":"10.1371\/journal.pone.0068343","article-title":"Indolent small intestinal CD4+ T-cell lymphoma is a distinct entity with unique biologic and clinical features.","volume":"8","author":"E Margolskee","year":"2013","journal-title":"PLoS One."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"1067-79","DOI":"10.6004\/jnccn.2016.0117","article-title":"NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.","volume":"14","author":"S Horwitz","year":"2016","journal-title":"J Natl Compr Canc Netw."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"v108-15","DOI":"10.1093\/annonc\/mdv201","article-title":"Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"26 Suppl 5","author":"F d'Amore","year":"2015","journal-title":"Ann Oncol."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"1467-75","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification.","volume":"15","author":"K Savage","year":"2004","journal-title":"Ann Oncol."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"4124-30","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes.","volume":"26","author":"J Vose","year":"2008","journal-title":"J Clin Oncol."},{"key":"ref-27","doi-asserted-by":"publisher","DOI":"10.5402\/2011\/623924","article-title":"A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma.","volume":"2011","author":"A Abouyabis","year":"2011","journal-title":"ISRN Hematol."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"2091-8","DOI":"10.1002\/cncr.20999","article-title":"Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.","volume":"103","author":"M Escal\u00f3n","year":"2005","journal-title":"Cancer."},{"key":"ref-29","first-page":"943-6","article-title":"[Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].","volume":"23","author":"Y Peng","year":"2004","journal-title":"Ai Zheng."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"159-66","DOI":"10.1111\/j.1365-2141.2010.08329.x","article-title":"Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.","volume":"151","author":"A Simon","year":"2010","journal-title":"Br J Haematol."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"4284-9","DOI":"10.1182\/blood-2003-02-0542","article-title":"Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.","volume":"102","author":"H Tilly","year":"2003","journal-title":"Blood."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"582-8","DOI":"10.1111\/j.1365-2141.2011.08634.x","article-title":"Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers.","volume":"153","author":"N Niitsu","year":"2011","journal-title":"Br J Haematol."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"626-33","DOI":"10.1182\/blood-2003-06-2094","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.","volume":"104","author":"M Pfreundschuh","year":"2004","journal-title":"Blood."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"634-41","DOI":"10.1182\/blood-2003-06-2095","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.","volume":"104","author":"M Pfreundschuh","year":"2004","journal-title":"Blood."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"371-9","DOI":"10.1002\/cncr.27733","article-title":"Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.","volume":"119","author":"D Mahadevan","year":"2013","journal-title":"Cancer."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"35-9","DOI":"10.1007\/s00280-005-0136-y","article-title":"CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas.","volume":"58","author":"J Kim","year":"2006","journal-title":"Cancer Chemother Pharmacol."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"75-6","DOI":"10.1002\/hon.2437_63","article-title":"CHOP VERSUS GEM-P IN THE FIRST-LINE TREATMENT OF T-CELL LYMPHOMA (PTCL): INITIAL RESULTS OF THE UK NRCI PHASE II RANDOMISED CHEMO-T TRIAL.","volume":"35","author":"M Gleeson","year":"2017","journal-title":"Hematol Oncol."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"106-13","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study.","volume":"27","author":"P Reimer","year":"2009","journal-title":"J Clin Oncol."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"3093-9","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.","volume":"30","author":"F d'Amore","year":"2012","journal-title":"J Clin Oncol."},{"key":"ref-40","first-page":"139-140","article-title":"TEN YEARS MEDIAN FOLLOW-UP OF THE NORDIC NLG-T-01 TRIAL ON CHOEP AND UPFRONT AUTOLOGOUS TRANSPLANTATION IN PERIPHERAL T-CELL LYMPHOMAS.","volume":"33","author":"F d'Amore","year":"2015","journal-title":"Hematol Oncol."},{"key":"ref-41","first-page":"8507-8507","article-title":"Allogeneic or autologous transplantation as first-line therapy for younger patients with peripheral T-cell lymphoma: Results of the interim analysis of the AATT trial","volume":"33","author":"M Norbert Schmitz","year":"2015","journal-title":"J Clin Oncol."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"855-9","DOI":"10.1016\/j.bbmt.2015.01.013","article-title":"Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease.","volume":"21","author":"A Beitinjaneh","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"1970-6","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.","volume":"31","author":"V Mak","year":"2013","journal-title":"J Clin Oncol."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"2920-4","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas.","volume":"103","author":"G Enblad","year":"2004","journal-title":"Blood."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"390-2","DOI":"10.1093\/annonc\/mdn726","article-title":"Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study.","volume":"20","author":"S Kim","year":"2009","journal-title":"Ann Oncol."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"447-55","DOI":"10.3109\/10428190903580402","article-title":"A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.","volume":"51","author":"E Weidmann","year":"2010","journal-title":"Leuk Lymphoma."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"5425-30","DOI":"10.1200\/JCO.2009.22.6688","article-title":"Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.","volume":"27","author":"F Ravandi","year":"2009","journal-title":"J Clin Oncol."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"129-34","DOI":"10.1007\/s00280-007-0469-9","article-title":"Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study.","volume":"60","author":"J Kim","year":"2007","journal-title":"Cancer Chemother Pharmacol."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"1595-600","DOI":"10.1093\/annonc\/mdq635","article-title":"Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma.","volume":"22","author":"H Kluin-Nelemans","year":"2011","journal-title":"Ann Oncol."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"2316-23","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.","volume":"110","author":"A Gallamini","year":"2007","journal-title":"Blood."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"1521-8","DOI":"10.1007\/s00277-013-1880-4","article-title":"CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial.","volume":"92","author":"C Binder","year":"2013","journal-title":"Ann Hematol."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"2190-6","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.","volume":"30","author":"B Pro","year":"2012","journal-title":"J Clin Oncol."},{"key":"ref-53","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood.V124.21.3095.3095","article-title":"Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.","volume":"124","author":"B Pro","year":"2014","journal-title":"Blood."},{"key":"ref-54","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood.V128.22.4144.4144","article-title":"Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.","volume":"128","author":"B Pro","year":"2016","journal-title":"Blood."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"3402-8","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project.","volume":"117","author":"D Weisenburger","year":"2011","journal-title":"Blood."},{"key":"ref-56","first-page":"509-19","article-title":"Study of the immunohistochemistry and T cell clonality of enteropathy-associated T cell lymphoma.","volume":"146","author":"A Murray","year":"1995","journal-title":"Am J Pathol."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"343-51","DOI":"10.1309\/V561QTM6854W4WAV","article-title":"Immunohistochemical characterization of nasal-type extranodal NK\/T-cell lymphoma using a tissue microarray: an analysis of 84 cases.","volume":"130","author":"E Schwartz","year":"2008","journal-title":"Am J Clin Pathol."},{"key":"ref-58","doi-asserted-by":"publisher","first-page":"3095-100","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.","volume":"123","author":"S Horwitz","year":"2014","journal-title":"Blood."},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"3137-43","DOI":"10.1200\/JCO.2013.54.2456","article-title":"Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.","volume":"32","author":"M Fanale","year":"2014","journal-title":"J Clin Oncol."},{"key":"ref-60","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1182\/blood.V128.22.2993.2993","article-title":"Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas","volume":"128","author":"M Fanale","year":"2016","journal-title":"Blood."},{"key":"ref-61","first-page":"3625-34","article-title":"Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: its close association with skin involvement and unfavorable outcome.","volume":"9","author":"T Ishida","year":"2003","journal-title":"Clin Cancer Res."},{"key":"ref-62","doi-asserted-by":"publisher","first-page":"5494-500","DOI":"10.1158\/1078-0432.CCR-04-0371","article-title":"CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified.","volume":"10","author":"T Ishida","year":"2004","journal-title":"Clin Cancer Res."},{"key":"ref-63","doi-asserted-by":"crossref","first-page":"685-90","DOI":"10.1182\/blood.V96.2.685","article-title":"Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma.","volume":"96","author":"D Jones","year":"2000","journal-title":"Blood."},{"key":"ref-64","doi-asserted-by":"publisher","first-page":"1157-63","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.","volume":"32","author":"M Ogura","year":"2014","journal-title":"J Clin Oncol."},{"key":"ref-65","doi-asserted-by":"publisher","first-page":"e160-5","DOI":"10.1016\/S2352-3026(15)00023-X","article-title":"Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b\/2 study.","volume":"2","author":"J Dupuis","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref-66","doi-asserted-by":"publisher","first-page":"3220-4","DOI":"10.1182\/blood-2007-05-085159","article-title":"PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.","volume":"111","author":"R Yamamoto","year":"2008","journal-title":"Blood."},{"key":"ref-67","doi-asserted-by":"publisher","first-page":"5359-70","DOI":"10.1182\/blood-2007-08-105395","article-title":"Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma.","volume":"111","author":"S Mittal","year":"2008","journal-title":"Blood."},{"key":"ref-68","doi-asserted-by":"publisher","first-page":"802-10","DOI":"10.1097\/01.pas.0000209855.28282.ce","article-title":"Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma.","volume":"30","author":"D Dorfman","year":"2006","journal-title":"Am J Surg Pathol."},{"key":"ref-69","doi-asserted-by":"publisher","first-page":"3462-73","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.","volume":"19","author":"B Chen","year":"2013","journal-title":"Clin Cancer Res."},{"key":"ref-70","doi-asserted-by":"publisher","first-page":"2698-704","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.","volume":"34","author":"A Lesokhin","year":"2016","journal-title":"J Clin Oncol."},{"key":"ref-71","doi-asserted-by":"publisher","first-page":"1913-5","DOI":"10.1007\/s00277-016-2764-1","article-title":"Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety.","volume":"95","author":"T Chan","year":"2016","journal-title":"Ann Hematol."},{"key":"ref-72","doi-asserted-by":"publisher","first-page":"2437-42","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase.","volume":"129","author":"Y Kwong","year":"2017","journal-title":"Blood."},{"key":"ref-73","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.183.183","article-title":"A Phase 1 Study of Nivolumab in Combination with Ipilimumab for Relapsed or Refractory Hematologic Malignancies (CheckMate 039).","author":"S Ansell","year":"2016"},{"key":"ref-74","doi-asserted-by":"publisher","first-page":"6657-61","DOI":"10.1158\/1078-0432.CCR-12-2251","article-title":"Pralatrexate pharmacology and clinical development.","volume":"19","author":"E Marchi","year":"2013","journal-title":"Clin Cancer Res."},{"key":"ref-75","doi-asserted-by":"publisher","first-page":"4357-64","DOI":"10.1200\/JCO.2008.20.8470","article-title":"Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.","volume":"27","author":"O O'Connor","year":"2009","journal-title":"J Clin Oncol."},{"key":"ref-76","doi-asserted-by":"publisher","first-page":"1182-9","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.","volume":"29","author":"O O'Connor","year":"2011","journal-title":"J Clin Oncol."},{"key":"ref-77","doi-asserted-by":"publisher","first-page":"2061-8","DOI":"10.1111\/cas.13340","article-title":"Phase I\/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma.","volume":"108","author":"D Maruyama","year":"2017","journal-title":"Cancer Sci."},{"key":"ref-78","doi-asserted-by":"publisher","first-page":"924-32","DOI":"10.1158\/1078-0432.CCR-05-0331","article-title":"The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma.","volume":"12","author":"L Toner","year":"2006","journal-title":"Clin Cancer Res."},{"key":"ref-79","doi-asserted-by":"publisher","first-page":"3648-58","DOI":"10.1158\/1078-0432.CCR-10-0671","article-title":"Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies.","volume":"16","author":"E Marchi","year":"2010","journal-title":"Clin Cancer Res."},{"key":"ref-80","doi-asserted-by":"publisher","first-page":"535-44","DOI":"10.1111\/bjh.13855","article-title":"A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.","volume":"172","author":"R Advani","year":"2016","journal-title":"Br J Haematol."},{"key":"ref-81","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1182\/blood.V114.22.1674.1674","article-title":"Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies: Phase 1 Results.","volume":"114","author":"S Horwitz","year":"2009","journal-title":"Blood."},{"key":"ref-82","doi-asserted-by":"publisher","first-page":"1160-3","DOI":"10.3346\/jkms.2016.31.7.1160","article-title":"Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients.","volume":"31","author":"S Lee","year":"2016","journal-title":"J Korean Med Sci."},{"key":"ref-83","doi-asserted-by":"publisher","first-page":"1210-6","DOI":"10.1093\/jnci\/92.15.1210","article-title":"Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.","volume":"92","author":"P Marks","year":"2000","journal-title":"J Natl Cancer Inst."},{"key":"ref-84","doi-asserted-by":"publisher","first-page":"769-84","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors.","volume":"5","author":"J Bolden","year":"2006","journal-title":"Nat Rev Drug Discov."},{"key":"ref-85","doi-asserted-by":"publisher","first-page":"688-98","DOI":"10.1111\/j.1365-2559.2009.03290.x","article-title":"Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas.","volume":"54","author":"L Marquard","year":"2009","journal-title":"Histopathology."},{"key":"ref-86","doi-asserted-by":"publisher","first-page":"515-25","DOI":"10.1111\/j.1365-2141.2009.07887.x","article-title":"Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.","volume":"147","author":"A Gloghini","year":"2009","journal-title":"Br J Haematol."},{"key":"ref-87","doi-asserted-by":"publisher","first-page":"2865-8","DOI":"10.1182\/blood.V98.9.2865","article-title":"Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report.","volume":"98","author":"R Piekarz","year":"2001","journal-title":"Blood."},{"key":"ref-88","doi-asserted-by":"publisher","first-page":"5827-34","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.","volume":"117","author":"R Piekarz","year":"2011","journal-title":"Blood."},{"key":"ref-89","doi-asserted-by":"publisher","first-page":"631-6","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.","volume":"30","author":"B Coiffier","year":"2012","journal-title":"J Clin Oncol."},{"key":"ref-90","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.","volume":"7","author":"B Coiffier","year":"2014","journal-title":"J Hematol Oncol."},{"key":"ref-91","doi-asserted-by":"publisher","first-page":"655-65","DOI":"10.1007\/s12185-017-2286-1","article-title":"Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I\/II and pharmacokinetics study.","volume":"106","author":"D Maruyama","year":"2017","journal-title":"Int J Hematol."},{"key":"ref-92","doi-asserted-by":"publisher","first-page":"125-36","DOI":"10.1002\/ijc.29698","article-title":"Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.","volume":"138","author":"K Hui","year":"2016","journal-title":"Int J Cancer."},{"key":"ref-93","doi-asserted-by":"publisher","first-page":"508-13","DOI":"10.1093\/annonc\/mdv596","article-title":"Epstein-Barr virus reactivation in extranodal natural killer\/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin.","volume":"27","author":"S Kim","year":"2016","journal-title":"Ann Oncol."},{"key":"ref-94","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-016-0266-1","article-title":"A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed\/refractory peripheral T-cell lymphoma patients.","volume":"9","author":"C Pellegrini","year":"2016","journal-title":"J Hematol Oncol."},{"key":"ref-95","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1182\/blood.V128.22.4162.4162","article-title":"A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma: Canadian Cancer Trials Group Study LY.","volume":"128","author":"T Reiman","year":"2016","journal-title":"Blood."},{"key":"ref-96","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1182\/blood.V126.23.3987.3987","article-title":"High Response Rate of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Updates of Phase I Trial.","volume":"126","author":"D Chihara","year":"2015","journal-title":"Blood."},{"key":"ref-97","doi-asserted-by":"publisher","first-page":"811-9","DOI":"10.1111\/bjh.13222","article-title":"A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.","volume":"168","author":"F Foss","year":"2015","journal-title":"Br J Haematol."},{"key":"ref-98","doi-asserted-by":"publisher","first-page":"2492-9","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.","volume":"33","author":"O O'Connor","year":"2015","journal-title":"J Clin Oncol."},{"key":"ref-99","article-title":"Belinostat in relapsed or refractory peripheral T-cell lymphoma (R\/R PTCL) subtype angioimmunoblastic T-cell lymphoma (AITL): Results from the pivotal BELIEF trial.","author":"S Horwitz","year":"2013"},{"key":"ref-100","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood.V126.23.253.253","article-title":"Safe and Effective Treatment of Patients with Peripheral T-Cell Lymphoma (PTCL) with the Novel HDAC Inhibitor, Belinostat, in Combination with CHOP: Results of the Bel-CHOP Phase 1 Trial.","volume":"126","author":"P Johnston","year":"2015","journal-title":"Blood."},{"key":"ref-101","doi-asserted-by":"publisher","first-page":"901-9","DOI":"10.1007\/s00280-011-1766-x","article-title":"Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.","volume":"69","author":"Z Ning","year":"2012","journal-title":"Cancer Chemother Pharmacol."},{"key":"ref-102","doi-asserted-by":"publisher","first-page":"1766-71","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.","volume":"26","author":"Y Shi","year":"2015","journal-title":"Ann Oncol."},{"key":"ref-103","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","article-title":"Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.","volume":"10","author":"Y Shi","year":"2017","journal-title":"J Hematol Oncol."},{"key":"ref-104","doi-asserted-by":"publisher","first-page":"138-41","DOI":"10.1111\/bjh.12326","article-title":"Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma.","volume":"162","author":"Y Oki","year":"2013","journal-title":"Br J Haematol."},{"key":"ref-105","doi-asserted-by":"publisher","first-page":"459-62","DOI":"10.1007\/s00277-014-2009-0","article-title":"Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed\/refractory peripheral T cell lymphoma (PTCL): report of a phase I\/II trial.","volume":"93","author":"G Hopfinger","year":"2014","journal-title":"Ann Hematol."},{"key":"ref-106","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood.V124.21.503.503","article-title":"A Phase 2 Study of Panobinostat (PAN) in Combination with Bortezomib (BTZ) in Patients with Relapsed\/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK\/T-Cell Lymphoma (NKL).","volume":"124","author":"Y Goh","year":"2014","journal-title":"Blood."},{"key":"ref-107","doi-asserted-by":"publisher","first-page":"2471-6","DOI":"10.1182\/blood-2014-11-567792","article-title":"Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities.","volume":"125","author":"A Kritharis","year":"2015","journal-title":"Blood."},{"key":"ref-108","doi-asserted-by":"publisher","first-page":"2869-76","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.","volume":"49","author":"F Morschhauser","year":"2013","journal-title":"Eur J Cancer."},{"key":"ref-109","doi-asserted-by":"publisher","first-page":"716-23","DOI":"10.1002\/cncr.29103","article-title":"Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma.","volume":"121","author":"E Toumishey","year":"2015","journal-title":"Cancer."},{"key":"ref-110","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood.V128.22.2991.2991","article-title":"A Phase Ib\/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed\/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas.","volume":"128","author":"N Mehta-Shah","year":"2016","journal-title":"Blood."},{"key":"ref-111","doi-asserted-by":"publisher","first-page":"772-80","DOI":"10.1111\/bjh.14763","article-title":"The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers.","volume":"178","author":"L Li","year":"2017","journal-title":"Br J Haematol."},{"key":"ref-112","doi-asserted-by":"publisher","first-page":"4293-7","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.","volume":"25","author":"P Zinzani","year":"2007","journal-title":"J Clin Oncol."},{"key":"ref-113","doi-asserted-by":"publisher","first-page":"859-68","DOI":"10.1038\/sj.onc.1204168","article-title":"Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin.","volume":"20","author":"A Arlt","year":"2001","journal-title":"Oncogene."},{"key":"ref-114","doi-asserted-by":"publisher","first-page":"3223-31","DOI":"10.1016\/j.ejca.2012.06.003","article-title":"Bortezomib in combination with CHOP as first-line treatment for patients with stage III\/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.","volume":"48","author":"S Kim","year":"2012","journal-title":"Eur J Cancer."},{"key":"ref-115","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1200\/jco.2009.27.15_suppl.8554","article-title":"A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: results of the GELA LNH05-1T trial.","volume":"27","author":"A Delmer","year":"2009","journal-title":"J Clin Oncol."},{"key":"ref-116","doi-asserted-by":"publisher","first-page":"627-44","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer.","volume":"8","author":"P Liu","year":"2009","journal-title":"Nat Rev Drug Discov."},{"key":"ref-117","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1182\/blood.V124.21.803.803","article-title":"Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-\u03b4,\u03b3 Inhibitor, Shows Activity in Patients with Relapsed\/Refractory T-Cell Lymphoma.","volume":"124","author":"M Steven","year":"2014","journal-title":"Blood."},{"key":"ref-118","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/hon.2439_191","article-title":"Dual Pi3k \u03b4\/\u03b3 Inhibitor Rp6530 In Patients With Relapsed\/Refractory T-Cell Lymphoma: Dose Escalation Findings.","volume":"35","author":"Y Oki","year":"2017","journal-title":"Hematol Oncol."},{"key":"ref-119","doi-asserted-by":"publisher","first-page":"2169-78","DOI":"10.1093\/annonc\/mdx289","article-title":"Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.","volume":"28","author":"M Dreyling","year":"2017","journal-title":"Ann Oncol."},{"key":"ref-120","first-page":"2465-74","article-title":"The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma.","volume":"35","author":"J Hong","year":"2015","journal-title":"Anticancer Res."},{"key":"ref-121","doi-asserted-by":"publisher","first-page":"463-70","DOI":"10.1111\/bjh.13603","article-title":"Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma.","volume":"171","author":"Y Oki","year":"2015","journal-title":"Br J Haematol."},{"key":"ref-122","doi-asserted-by":"publisher","first-page":"11988-93","DOI":"10.1073\/pnas.1310230110","article-title":"Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers.","volume":"110","author":"M Pourdehnad","year":"2013","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-123","doi-asserted-by":"publisher","first-page":"712-8","DOI":"10.1093\/annonc\/mdv624","article-title":"A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas.","volume":"27","author":"S Kim","year":"2016","journal-title":"Ann Oncol."},{"key":"ref-124","doi-asserted-by":"publisher","first-page":"328-35","DOI":"10.1182\/blood-2015-02-629543","article-title":"The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.","volume":"126","author":"T Witzig","year":"2015","journal-title":"Blood."},{"key":"ref-125","doi-asserted-by":"publisher","first-page":"104-10","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.","volume":"31","author":"G Damaj","year":"2013","journal-title":"J Clin Oncol."},{"key":"ref-126","doi-asserted-by":"publisher","first-page":"393-4","DOI":"10.1002\/hon.2439_161","article-title":"A Phase II Trial Of Bendamustine, Carboplatin And Dexamethasone (BCD) For Refractory Or Relapsed Peripheral T-Cell Lymphoma (BENCART): A Consortium For Improving Survival Of Lymphoma (CISL) Trial.","volume":"35","author":"B Park","year":"2017","journal-title":"Hematol Oncol."},{"key":"ref-127","doi-asserted-by":"publisher","first-page":"640-7","DOI":"10.1038\/modpathol.2012.211","article-title":"Differential expression of aurora-A kinase in T-cell lymphomas.","volume":"26","author":"R Kanagal-Shamanna","year":"2013","journal-title":"Mod Pathol."},{"key":"ref-128","doi-asserted-by":"publisher","first-page":"44-50","DOI":"10.1200\/JCO.2012.46.8793","article-title":"Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.","volume":"32","author":"J Friedberg","year":"2014","journal-title":"J Clin Oncol."},{"key":"ref-129","doi-asserted-by":"publisher","first-page":"2399-404","DOI":"10.1200\/JCO.2014.60.6327","article-title":"Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.","volume":"33","author":"P Barr","year":"2015","journal-title":"J Clin Oncol."},{"key":"ref-130","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1182\/blood.V126.23.341.341","article-title":"First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed\/Refractory (R\/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice.","volume":"126","author":"O O'Connor","year":"2015","journal-title":"Blood."},{"key":"ref-131","doi-asserted-by":"publisher","first-page":"4882-9","DOI":"10.1182\/blood-2011-02-334904","article-title":"Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.","volume":"118","author":"T Witzig","year":"2011","journal-title":"Blood."},{"key":"ref-132","doi-asserted-by":"publisher","first-page":"251-2","DOI":"10.1002\/hon.2438_115","article-title":"Preliminary Results From An Open-Label, Phase II Study Of Tipifarnib In Relapsed Or Refractory Peripheral T-Cell Lymphoma.","volume":"35","author":"T Witzig","year":"2017","journal-title":"Hematol Oncol."},{"key":"ref-133","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2049-3002-2-4","article-title":"A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process.","volume":"2","author":"S Stuart","year":"2014","journal-title":"Cancer Metab."},{"key":"ref-134","doi-asserted-by":"publisher","first-page":"5255-64","DOI":"10.1158\/1078-0432.CCR-14-1019","article-title":"A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies.","volume":"20","author":"T Pardee","year":"2014","journal-title":"Clin Cancer Res."},{"key":"ref-135","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood.V128.22.4163.4163","article-title":"Phase I Dose-Escalation Study of Cpi-613, in Combination with Bendamustine, in Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma","volume":"128","author":"Z Lamar","year":"2016","journal-title":"Blood."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/6-2123\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/6-2123\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/6-2123\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T05:27:08Z","timestamp":1603517228000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/6-2123\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,12]]},"references-count":135,"URL":"https:\/\/doi.org\/10.12688\/f1000research.12573.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.13616.r28593","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.13616.r28596","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,12]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/6-2123\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.13616.r28593, Christian Gisselbrecht, Institut d'H\u00e9matologie, H\u00f4pital Saint-Louis, Paris, France, 12 Dec 2017, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/6-2123\/v1#referee-response-28593","order":0,"name":"referee-response-28593","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.13616.r28596, Shigeru Chiba, Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 12 Dec 2017, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/6-2123\/v1#referee-response-28596","order":1,"name":"referee-response-28596","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}